The Knight Family DIAN-TU-003 Amyloid Removal Trial
DIAN-TU is launching the DIAN-TU-003 Amyloid Removal Trial (ART) to enable continued treatment for the DIAN-TU-001 Gantenerumab Open Label Extension (OLE) participants and address questions regarding the effects of removing amyloid plaques to normal levels on cognitive symptoms, clinical progression and disease processes.
The Knight Family DIAN-TU Primary Prevention Trial
We are now pleased to announce plans to re-launch the DIAN-TU-002 Primary Prevention Trial with remternetug in collaboration with Eli Lilly and Company (Lilly).
The Knight Family DIAN-TU Amyloid Removal Trial
Update to the 18 August 2023 announcement by the Knight Family DIAN-TU regarding the DIAN-TU-001 Open Label Extension (OLE) Study
Update on the DIAN-TU-001 Gantenerumab Open Label Extension
This announcement is regarding the Knight Family DIAN-TU Open Label Extension (OLE) Study with gantenerumab (made by Roche and Genentech)
Update on the DIAN-TU-001 Open Label Extension with Gantenerumab (Roche/Genentech)
Questions and concerns from sites and participants regarding the status of the DIAN-TU-001 gantenerumab open label extension (OLE) study and next steps in the study.
Update on the DIAN-TU-001 Trial with E2814 and Lecanemab (Eisai Co., Ltd)
Response to Eisai’s 06 January 2023 announcement regarding the FDA’s accelerated approval of lecanemab for the treatment of symptomatic Alzheimer’s disease (AD)
Update on the DIAN-TU-002 Primary Prevention Trial
Update to the 15 November 2022 announcement by the Knight Family Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) regarding the DIAN-TU-002 Primary Prevention Trial with Gantenerumab.
Update on the DIAN-TU-001 Open Label Extension and DIAN-TU-002 Primary Prevention Trials with Gantenerumab (Roche/Genentech)
The statement below is in response to the 14 November 2022 announcement regarding the results from the GRADUATE I and II AD studies found on Roche’s website. Roche, known as Genentech in the United States, and the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) at Washington University in St. Louis have been evaluating gantenerumab in […]
Update on the DIAN-TU-001 Open Label Extension and DIAN-TU-002 Primary Prevention Trials with Gantenerumab (Roche/Genentech)
Response to the 14-November-2022 announcement regarding the results from the GRADUATE I and II AD studies found on Roche’s website
Update on the DIAN-TU-001 Trial with E2814 and Investigational Lecanemab (Eisai Co., Ltd)
Response to the 28 September 2022 announcement found on Eisai’s website.
New eligibility criteria for participation in Tau NexGen E2814: A requirement for participants to learn their genetic status prior to enrollment
The new Tau NexGen E2814 clinical trial planned for DIAN-TU will be launching at most sites in 2022. This new trial design will offer individuals who have a dominantly inherited Alzheimer’s disease (DIAD) mutation access to investigational drugs that target both amyloid and tau. All participants will receive the anti-amyloid drug and also be randomized […]
Gantenerumab improved markers of disease in rare, inherited form of Alzheimer’s disease
Further analysis of data from an international trial of two investigational drugs in people in the early stages of a rare, inherited form of Alzheimer’s disease has demonstrated that one of the drugs had a positive impact on biomarkers of the disease. The study (ClinicalTrials.gov Identifier: NCT01760005) is a phase 2/3 trial led by Washington […]
Investigational drugs didn’t slow memory loss, cognitive decline in rare, inherited Alzheimer’s, initial analysis indicates (Links to an external site)
Top-line data reported from international trial
Update on the DIAN-TU-001 TRIAL: Janssen BACE Inhibitor (JNJ-54861911/atabecestat) DRUG ARM DISCONTINUATION
Update to the May 25th announcement found on Janssen’s website
DIAN-TU-001 Interim Analysis
Notice to DIAN-TU Investigational Sites and Participants
2015 Update
The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) has completed the first stage of participant enrollment in the first Alzheimer’s prevention trial for autosomal dominant Alzheimer’s disease (ADAD), also referred to as early-onset Alzheimer’s disease. The goal of the first stage of the study is to determine the biomarker and cognitive effects of two different […]
